

Brain Development Research Consortium

 consortiapedia.fastercures.org/consortia/bdrc/

Research Areas



Basic Research

At a Glance

- Status: **Active Consortium**
- Year Launched: **2014**
- Initiating Organization: **Astellas, Eli Lilly and Company, Lundbeck, Pfizer, and Roche**
- Initiator Type: **Industry**
- Location: **International**

Abstract

The Lieber Institute for Brain Development and pharmaceutical companies Astellas, Eli Lilly and Company, Lundbeck, Pfizer Inc., and Roche are participating in an early-stage research consortium to analyze ribonucleic acid (RNA), the genomic and epigenetic data obtained from human brains.

Mission

This consortium is a bold initiative with the potential to have broad relevance across the spectrum of human brain disorders. By uniting diverse scientists from different sectors, it has created a new model of cooperative research that is designed to accomplish ambitious goals with efficiency and focus.

Astellas, Eli Lilly and Company, Lundbeck, Pfizer, and Roche, as members of the consortium, will seek to convert basic scientific findings into new treatment options for people living with developmental brain disorders.

Consortium History

March 2014: Consortium announced

Links/Social Media Feed

Other website

<http://libd.org/research-activities/our-news/2014/lieber-institute-announces-consortium-to-identify-how-genes-build-a-brain-with-the-goal-of-developing-treatments-for-brain-disorders>

Sponsors & Partners

Astellas

Eli Lilly and Company

Lieber Institute for Brain Development

Lundbeck

Pfizer Inc.

Roche

Updated: **04/14/2016**